GlassScriptPhysician profile
Jan Prusinowski
NPI 1366413411
$3,205.52
in general payments reported to CMS, 2019-2025
23 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,030 · 2022: $605 · 2023: $586 · 2024: $378 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $443.20 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $320.35 | 2021-2025 | |
| Amgen INC. | $297.59 | 2021-2025 | Otezla, Enbrel, Otezla |
| Janssen Biotech, INC. | $286.14 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $259.17 | 2021-2025 | Dupixent |
| Abbvie INC. | $237.28 | 2021-2024 | |
| Leo Pharma INC. | $235.84 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $227.38 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $213.41 | 2021-2024 | |
| Lilly USA, LLC | $148.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.51 | 2021-2022 | |
| Incyte Corporation | $87.55 | 2023-2025 | Opzelura |
| Organon LLC | $66.89 | 2025 | Vtama |
| Dermavant Sciences, INC. | $60.95 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $50.62 | 2021-2025 | Nemluvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $37.87 | 2023-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $25.27 | 2023 | |
| Fresenius Kabi USA, LLC | $22.28 | 2023 | |
| Vyne Pharmaceuticals INC. | $19.19 | 2021 | |
| Almirall LLC | $17.05 | 2022 | |
| Journey Medical Corporation | $15.77 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.38 | 2024 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Prusinowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.